2023
The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease
Jirapinyo P, Thompson C, Garcia-Tsao G, Zucker S, Ryou M. The effect of endoscopic gastric plication on portosystemic pressure gradient in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Endoscopy 2023, 56: 56-62. PMID: 37532114, DOI: 10.1055/a-2146-8857.Peer-Reviewed Original ResearchMeSH KeywordsHumansLiverLiver CirrhosisNon-alcoholic Fatty Liver DiseasePilot ProjectsProspective StudiesTreatment OutcomeWeight LossConceptsNonalcoholic fatty liver diseaseEndoscopic gastric plicationAdvanced chronic liver diseaseFatty liver diseasePortosystemic pressure gradientChronic liver diseaseLiver diseaseTotal weight lossGastric plicationNoninvasive testsBaseline median body-mass indexMedian body mass indexPercent total weight lossWeight lossProportion of patientsProspective pilot studyBody mass indexLiver stiffness measurementWeight loss proceduresGoal of therapyHepatic decompensationSecondary outcomesPrimary outcomeMass indexPatientsMachine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
Noureddin M, Goodman Z, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Garcia‐Tsao G, Harrison S, Chalasani N. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis. Alimentary Pharmacology & Therapeutics 2023, 57: 409-417. PMID: 36647687, PMCID: PMC10107331, DOI: 10.1111/apt.17363.Peer-Reviewed Original ResearchMeSH KeywordsFibrosisHumansHypertension, PortalLiverLiver CirrhosisNon-alcoholic Fatty Liver DiseasePortal PressureVaricose VeinsConceptsHepatic venous pressure gradientPresence of varicesEnd of treatmentValidation cohortLiver histology scoresPhase 2b trialPrimary efficacy endpointVenous pressure gradientDevelopment of varicesNonalcoholic steatohepatitis cirrhosisImportant histologic featuresImportant clinical relevanceHVPG changesEfficacy endpointHVPG measurementLiver histologyUpper endoscopyLiver biopsyLiver outcomesHistologic variablesNASH cirrhosisHistologic featuresHypertension assessmentCirrhosis (HALT-C) TrialClinical trials
2022
Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model
Rabiee A, Deng Y, Ciarleglio M, Chan JL, Pons M, Genesca J, Garcia‐Tsao G. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model. Hepatology Communications 2022, 6: 3324-3334. PMID: 36214066, PMCID: PMC9701481, DOI: 10.1002/hep4.2091.Peer-Reviewed Original ResearchMeSH KeywordsElasticity Imaging TechniquesHumansHypertension, PortalLiver CirrhosisNon-alcoholic Fatty Liver DiseasePortal PressureConceptsHepatic venous pressure gradientSignificant portal hypertensionTransient elastographyNASH cirrhosisPortal hypertensionFibrosis-4 indexPresence of CSPHVenous pressure gradientNonalcoholic steatohepatitis cirrhosisBody mass indexLiver stiffness measurementGood calibrationCompensated cirrhosisFIB-4Mass indexPlatelet countValidation cohortNoninvasive predictorTraining cohortBaseline riskLaboratory valuesCirrhosisHigh riskSeparate cohortNoninvasive surrogate
2021
Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!
Zanetto A, Senzolo M, Campello E, Bulato C, Gavasso S, Saggiorato G, Feltracco P, Farinati F, Russo FP, Burra P, Garcia‐Tsao G, Simioni P. Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet! Transplant International 2021, 34: 1325-1327. PMID: 33932057, DOI: 10.1111/tri.13895.Peer-Reviewed Original Research
2020
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum
Noureddin M, Chan J, Barradas K, Dimick-Santos L, Schabel E, Omokaro S, Anania F, Myers R, Miller V, Sanyal A, Chalasani N, Group L, Anania F, Bajaj J, Barradas K, Berzigotti A, Birman P, Bosch J, Brower A, Calboli D, Chalasani N, Chan J, Charlton W, Dickinson K, Dimick-Santos L, Filozof C, Forsgren M, Fuchs M, Garcia-Tsao G, Gonzalez-Abraldes J, Gruss H, Hansen M, Hosman S, Imperial J, Jones D, Lalazar G, Leinhard O, Lyons E, McColgan B, Mehta R, Mesenbrink P, Miller V, Myers R, Noureddin M, Omokaro S, Pei V, Ratziu V, Regev A, Riccio R, Sanyal A, Schabel E, Seo S, Smith A, Szitanyi P, Traber P. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Gastroenterology 2020, 159: 422-427.e1. PMID: 32353369, DOI: 10.1053/j.gastro.2020.04.039.Commentaries, Editorials and LettersMeSH KeywordsClinical Trials as TopicConsensusDrugs, InvestigationalHealthy LifestyleHumansLiverLiver CirrhosisNon-alcoholic Fatty Liver DiseasePatient SelectionPractice Guidelines as TopicStakeholder Participation